This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:

$$R_1$$
 R_2
 OR_4
 R_5
 R_7
 $(CH_2)_n$

wherein the dotted line represents an unsaturation or a cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alknaoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and triflouroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, and 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a poly(alkylene oxide) polymer.

Claim 2 (original): A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula;

$$R_1$$
 R_2
 $CH_2)_n$

wherein the dotted line represents an unsaturation or a cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl an alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alknaoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo and triflouroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons and n is one of the integers 0, 1, 2, 3, 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a cellulose polymer.

Claim 3 (original): A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:

$$R_1$$
 R_2
 OR_4
 R_7
 $(CH_2)_n$

wherein the dotted line represents an unsaturation or a cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl an alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alknaoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo and triflouroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, and 4; and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a maltodextrin polymer.

Claim 4 (canceled)

Claim 5 (original): A dosage form for administering a drug to an environment of use, wherein the dosage form comprises a drug of the formula:

which dosage form comprises a member selected from the group consisting of a sustained-release dosage form and a controlled release dosage form, and wherein said dosage form comprises means for storing the drug and means for releasing the drug over an extended period of time.

Claim 6 (original): A dosage form for the oral delivery of a drug to an environment of use, wherein the dosage form comprises:

- (a) a wall comprising at least in part a composition permeable to the passage of fluid, which wall surrounds;
- (b) a compartment;
- (c) a drug composition in the compartment comprising a drug of the formula:

$$R_{5}$$
 R_{7}
 R_{1}
 R_{2}
 $CH_{2})_{n}$

Express Mail Label No. EV 324 304 336 US USSN: to be assigned, filed October 28, 2003 ARC2164USADIV2 Preliminary Amendment

wherein the dotted line represents a member selected from the group consisting of an unsaturation and cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alknaoyloxy of 2 to 7 carbon atoms, nitro, alkymercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo and trifluoroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is 0 to 4; and

- (d) a displacement in the compartment comprising a composition comprising an osmotically active compound; and,
- (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.

Claim 7 (canceled)